CARSGEN-B (02171) released its performance for the year 2025, with a net loss attributable to shareholders of 97.861 million yuan, narrowing by 87.7% year-on-year.

CARSGEN-B (02171) reported its annual performance for the year ending December 31, 2025, with revenue of 126 million yuan, up 218.7% year-on-year; the loss attributable to owners of the parent company narrowed to 97.861 million yuan, down 87.7% year-on-year; basic loss per share was 0.18 yuan. For the year ending December 31, 2025, the Group's revenue mainly came from Saikeze (autologous BCMA CAR-T cell product), for which the main revenue is calculated based on the ex-factory price rather than the terminal market price. The Group's revenue is recognized after the ex-factory delivery of the product is completed. Due to the necessary time period for CAR-T production, there is a discrepancy between the number of orders received from Huadong Medicine and the number of ex-factory deliveries.